GENFIT: Results from Ipsen's ELATIVE® pivotal Phase III

GENFIT: Results from Ipsen's ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

GENFIT: Results from Ipsen's ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United Kingdom , Saclay , France General , France , China , Cambridge , Cambridgeshire , Switzerland , Paris , United States , Shanghai , American , Amy Wolf , Ipsen Euronext , Anna Gibbins , Stephanie Boyer , Ioana Piscociu , Jean Christophe Marcoux , Christopher Bowlus , Christelle Huguet , Mo Christie , Nicolas Bogler , Nasdaq , University Of California Davis , Euronext , Global Head Of Franchise Communications , Uncertainties Of The Company , Head Of Research , Head Of Corporate Brand Strategy Communications Tel , Exchange Commission , Head Of Patient Services , Corporate Affairs , New England Journal , Primary Biliary , American Association , Liver Diseases , Primary Biliary Cholangitis , California Davis , Patient Services , Breakthrough Therapy Designation , Chronic Liver Failure , Urea Cycle Disorders , Organic Acidemias , Nasdaq Global Select Market , Rare Disease , Sponsored Level , American Depositary Receipt , Private Securities Litigation Reform Act , Registration Document , Half Year Business , Financial Report , French Autorit , Des March , Universal Registration Document , Christophe Marcoux , Chief Corporate Affairs Officer , Vice President , Investor Relations , Investor Relations Manager , Global Head , Franchise Communications , Senior Manager Global Media Relations , Corporate Brand Strategy ,